Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2133|177|6|1495-1502

ISSN： 0007-0963

Source： BRITISH JOURNAL OF DERMATOLOGY, Vol.177, Iss.6, 2017-12, pp. : 1495-1502

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Worldwide perspective of biosimilars for psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 177, Iss. 6, 2017-12 ,pp. : 1473-1473

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Shortcomings of Clinical Practice Guidelines

By  

Cardiology, Vol. 130, Iss. 3, 2015-03 ,pp. : 187-200

Karger

Access to resources Recommend Favorite

Biosimilars in Dermatology – theory becomes reality

By  

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 16, Iss. 2, 2018-02 ,pp. : 150-160

John Wiley & Sons Inc

Access to resources Recommend Favorite

Biosimilars and Regulatory Authorities

By  

Nephron Clin Pract, Vol. 117, Iss. 1, 2010-08 ,pp. : c1-c7

Karger

Access to resources Recommend Favorite

Frequency of undiagnosed psoriatic arthritis among psoriasis patients in Australian dermatology practice

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 11, 2015-11 ,pp. : 2184-2191

John Wiley & Sons Inc

Access to resources Recommend Favorite